Injectable Ocrevus® (ocrelizumab) listed on the PBS
4 December 2025
People with relapsing remitting MS can now access injectable Ocrevus® (ocrelizumab) through the Pharmaceutical Benefits Scheme.
People with relapsing remitting MS can now access injectable Ocrevus® (ocrelizumab) through the Pharmaceutical Benefits Scheme.
The report, Multiple Sclerosis Prevalence and Health Economic Impact in Australia 2025, commissioned by MS Australia and produced in collaboration with the Menzies Institute for Medical Research, University of Tasmania, reveals that a record 37,756 Australians are now living with the chronic neurological disease – a 13.3% increase in just three years since 2021.
CEO Rohan Greenland discusses the science and determination driving advances in causes, care, and cures at the upcoming 10th biennial Progress in MS Research Conference.
Muskaan shares her experience with MS diagnosis and the stigma of living with MS in her community. This deeply vulnerable article highlights cultural barriers to diagnosis disclosure and the importance of the lived experience voice.
Travelling with MS can be incredibly rewarding, but it requires thoughtful preparation to ensure comfort, safety, and accessibility. With the right strategies, you can enjoy less stressful adventures and make the most of your journey.
An online training programme helps healthcare providers feel more confident and skilled in delivering exercise programmes to people with MS.
The annual MS Nurses Australasia Conference in October highlighted the latest in best-practice holistic care for people with MS.
Fenebrutinib is a new treatment from the BTK inhibitor class, which aims to target immune cells throughout the body including the brain and spinal cord to treat MS.
CEO Rohan Greenland reflects on the growing international collaboration driving advances in MS research, treatment and care. He highlights how shared initiatives – from new diagnostic criteria to joint clinical trials – are helping the global MS community move faster toward cures.